AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8296077
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg/day (n = 29)
Trial: 31267688
Drug: Nurse-administered intraocular
RxNorm normalized name: PAD,NURSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-administered intraocular injections
Trial: 31267688
Drug: Physician-administered intraocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-administered intraocular injections
Trial: 30372645
Drug: Etonogestrel (ENG)
RxNorm normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etonogestrel (ENG) contraceptive implant
Trial: 30372645
Drug: 52 mg
RxNorm normalized name: papain 52 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 52 mg levonorgestrel-releasing intrauterine system (LNG-IUS)
Trial: 18248651
Drug: Evening GH
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening GH and/or morning hydrocortisone treatment
Trial: 18248651
Drug: Omission of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omission of evening GH and/or morning hydrocortisone treatment
Trial: 18248651
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with GH
Trial: 18248651
Drug: Omission of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omission of GH treatment
Trial: 18248651
Drug: Omission of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omission of GH treatment in PHDC+ patients
Trial: 18248651
Drug: Omission of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omission of GH treatment in patients with PHDC-
Trial: 18248651
Drug: Treatment and
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment and meals omission
Trial: 10473080
Drug: irinotecan (CPT‐11;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan (CPT‐11; 200 mg/m2) as a 90‐min i.v. infusion followed by cisplatin (CDDP; 80 mg/m2) as a 3‐h i.v. infusion
Trial: 28112575
Drug: International Warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: International Warfarin Pharmacogenetic Consortium algorithm
Trial: 26100229
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2, administered on day 1 every 21 days)
Trial: 26100229
Drug: Volasertib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib (300 mg, administered on day 1 every 21 days)
Trial: 25146063
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training and music therapy
Trial: 25146063
Drug: Pharmacotherapy (antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (antidepressant drugs)
Trial: 21148540
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of mononuclear bone marrow cells (n = 69)
Trial: 21148540
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of mononuclear peripheral blood cells (n = 66)
Trial: 21148540
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (n = 65)
Trial: 19300145
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration botulinum toxin A (100 U/ml)
Trial: 19300145
Drug: Low concentration
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low concentration botulinum toxin A (10 U/ml)
Trial: 9133941
Drug: Nasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal salmon calcitonin 200 IU daily
Trial: 3631942
Drug: Ciprofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (200 mg)
Trial: 30817543
Drug: Alcohol (96%)
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol (96%) solution
Trial: 30817543
Drug: Gentamicin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (80 mg) solution
Trial: 30817543
Drug: Formalin solution
RxNorm normalized name: formalin
DrugBank: Formaldehyde (DB03843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formalin solution
Trial: 30817543
Drug: Saline (0.9%)
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (0.9%) solution
Trial: 30817543
Drug: Cefazolin sodium
RxNorm normalized name: Cefazolin Sodium
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin sodium (Cezol 1gr) solution
Trial: 29664109
Drug: Forced fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forced fluid removal (using furosemide and/or continuous renal replacement therapy)
Trial: 21612045
Drug: Prophylactic measures
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic measures including oral cavity checkup, hygiene instruction, promotion of oral health, sealing of I permanent molar teeth
Trial: 18755727
Drug: Midazolam (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (5-10 mg)
Trial: 15926109
Drug: Canrenoate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canrenoate (400 mg)
Trial: 15926109
Drug: Canrenoate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canrenoate (400 mg) + Aldosterone (3 microg/minute)
Trial: 12576812
Drug: Neural network
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neural network algorithm based on urine levels of nuclear matrix protein‐22, monocyte chemoattractant protein‐1 and urinary intercellular adhesion molecule-1
Trial: 1899350
Drug: misoprostol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: misoprostol (600 micrograms daily) with diclofenac (150 mg daily)
Trial: 1899350
Drug: placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo with diclofenac (150 mg daily)
Trial: 6347119
Drug: Low-dose fluphenazine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fluphenazine decanoate (1.25 to 5.0 mg/2 wk)
Trial: 6347119
Drug: Standard-dose fluphenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose fluphenazine decanoate (12.5 to 50.0 mg/2 wk)
Trial: 6347119
Drug: Low-dose fluphenazine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fluphenazine decanoate
Trial: 20558037
Drug: Composite score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite score from cardiovascular therapy trial
Trial: 20558037
Drug: Binary composite
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Binary composite measure from cardiovascular therapy trial
Trial: 15962224
Drug: 4-drug antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-drug antiretroviral regimen
Trial: 12870834
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate dry powder inhaler (MF DPI) 400 microg twice daily
Trial: 12870834
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate dry powder inhaler (MF DPI) 800 microg twice daily
Trial: 1714697
Drug: Cow's milk
RxNorm normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow's milk infant formula with 40 mg Fe/100 g
Trial: 1714697
Drug: Cow's milk
RxNorm normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow's milk infant formula with 8.3 mg Fe/100 g
Trial: 26743348
Drug: Atorvastatin reload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin reload (AR) 80 mg 12 hours before + 40 mg 2 hours before PCI
Trial: 26743348
Drug: Atorvastatin reload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin reload (AR)
Trial: 20558006
Drug: Prednisolone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (5 mg and 10 mg)
Trial: 18089905
Drug: Caffeinated drink
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeinated drink (5 mg/kg)
Trial: 8648202
Drug: ca A/Los
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ca A/Los Angeles/2/87 (H3N2) vaccine
Trial: 8648202
Drug: bivalent ca
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent ca vaccine
Trial: 8648202
Drug: monovalent ca
RxNorm normalized name: CA-170
DrugBank: CA-170 (DB15772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monovalent ca H1N1 vaccine
Trial: 26666688
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy‐guided self‐help manual
Trial: 22417778
Drug: Bacteroides xylanisolvens
RxNorm normalized name: Bacteroides thetaiotaomicron
DrugBank: Bacteroides thetaiotaomicron (DB17879)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacteroides xylanisolvens DSM 23964 (10^12 cells) in spray-dried fermented milk for 6 weeks
Trial: 15024563
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml (15 mg) 0.5% hyperbaric bupivacaine (bilateral group)
Trial: 15024563
Drug: 1.5 ml
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml (7.5 mg) 0.5% hyperbaric bupivacaine (unilateral group)
Trial: 12350190
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care program (n = 447)
Trial: 2511696
Drug: pentaerythrityltetranitrate (PETN)
RxNorm normalized name: Pentaerythritol tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pentaerythrityltetranitrate (PETN) 50-300 mg
Trial: 2511696
Drug: isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: isosorbide dinitrate (ISDN) 40-120 mg
Trial: 2511696
Drug: sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual nitroglycerin
Trial: 981634
Drug: Large daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large daily fractions of 400 rads/day for 10-12 treatments
Trial: 11551733
Drug: Delayed-treatment control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-treatment control (DTC)
Trial: 9704701
Drug: Prolonged heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged heparin infusion after PTCA
Trial: 9704701
Drug: No postprocedure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postprocedure heparin (control group)
Trial: 25491493
Drug: Eluxadoline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eluxadoline (200 mg dose) coadministered with cyclosporine
Trial: 25491493
Drug: Eluxadoline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eluxadoline (200 mg dose) coadministered with probenecid
Trial: 20798655
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of calcium 20 min before exercise
Trial: 20798655
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of calcium every 15 min during exercise (1000 mg total)
Trial: 12956861
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (IgG) at doses of 1, 5, and 10 mg/ml
Trial: 2707117
Drug: 28 g
RxNorm normalized name: SM Syringe 28 g, 0.5cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 g sucrose during a mixed meal (meal A)
Trial: 25293368
Drug: AS03B-adjuvanted H5N1
RxNorm normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03B-adjuvanted H5N1 influenza vaccine (1.9 µg of hemagglutinin and 5.93 mg of α-tocopherol)
Trial: 25293368
Drug: AS03B-adjuvanted H5N1
RxNorm normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03B-adjuvanted H5N1 influenza vaccine
Trial: 21730902
Drug: Premature Infant
RxNorm normalized name: Premature infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premature Infant Oral Motor Intervention (PIOMI) for 5 minutes per day for 7 consecutive days
Trial: 9282969
Drug: Cholestyramine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (6 g/h)
Trial: 8332150
Drug: Other antiarrhythmic
RxNorm normalized name: Other antiarrhythmics, class I and III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antiarrhythmic drugs combined
Trial: 26983642
Drug: Oral PSORI-CM01
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral PSORI-CM01 plus topical sequential therapy
Trial: 26983642
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus topical sequential therapy
Trial: 26983642
Drug: Oral PSORI-CM01
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral PSORI-CM01
Trial: 17892610
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine (0.5%) + ketamine (0.1 mg kg‐1)
Trial: 17892610
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine (0.5%) + ketamine (0.1 mg kg‐1) + midazolam (0.02 mg kg‐1)
Trial: 12364444
Drug: Canrenoate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canrenoate (200 mg as an iv bolus, followed by 200 mg infused in 250 ml saline)
Trial: 12364444
Drug: Alprazolam (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.02 mg/kg, orally)
Trial: 10469814
Drug: Amethocaine gel
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amethocaine gel (1 g for 30 minutes)
Trial: 10469814
Drug: Lidocaine-prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-prilocaine cream (1 g for 60 minutes)
Trial: 1808626
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg aspirin daily
Trial: 1808626
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg aspirin daily
Trial: 6351586
Drug: Chromium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium supplementation (200 micrograms trivalent chromium daily for 6 weeks)
Trial: 23401275
Drug: Azithromycin combined
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin combined with prednisolone (treatment group, n = 28)
Trial: 19388505
Drug: Preoperative fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative fluid bolus (up to 1,000 mL using the 4‐2‐1 formula)
Trial: 11167354
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy plus training on the use of nasal spray (Group B)
Trial: 11167354
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy plus training on the use of nasal spray and a lesson on rhinitis and asthma (Group C)
Trial: 11167354
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy alone (Group A)
Trial: 9554567
Drug: rhIGF‐1 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐1 (80 µg/kg/day)
Trial: 9554567
Drug: rhIGF‐1 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐1 (80 µg/kg/day) + rhGH (50 µg/kg/day)
Trial: 7802322
Drug: Buccal prosidol
RxNorm normalized name: Prosol
DrugBank: Proline (DB00172)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal prosidol tablets
Trial: 3197580
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg intravenous bolus injection)
Trial: 31357997
Drug: Mass Testing
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass Testing and Treatment (MTaT) delivered by community health volunteers (CHVs) three times a year for 2 years
Trial: 21761706
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of allergen (SLIT)
Trial: 21761706
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray of budesonide (Control)
Trial: 19258920
Drug: Motavizumab 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motavizumab 15 mg/kg
Trial: 16961676
Drug: Drug only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug only (orlistat)
Trial: 16961676
Drug: Drug +
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug + brief counselling
Trial: 15532817
Drug: Cimetidine administered
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine administered at an early stage after bowel surgery while receiving parenteral nutrition
Trial: 11683207
Drug: Gonadotropin‐releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin‐releasing hormone agonist (GnRHa) alone or in combination with growth hormone (GH) for 3 years
Trial: 9804577
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (HP; 1.8 g . kg‐1 . day‐1)
Trial: 9804577
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (LP; 0.7 g . kg‐1 . day‐1)
Trial: 7933348
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (500 mg twice a day)
Trial: 3415422
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of fluphenazine decanoate (average, 25 mg every two weeks)
Trial: 3415422
Drug: Minimal dose
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal dose of fluphenazine decanoate (average, 3.8 mg every two weeks)
Trial: 30768663
Drug: Internal hex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal hex and convergent transmucosal collar implants
Trial: 30768663
Drug: Supracrestally placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supracrestally placed implants
Trial: 29941500
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine followed by metformin for 3 months and then metformin for 9 months
Trial: 29941500
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine followed by metformin
Trial: 17693905
Drug: Inhaled steroid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroid, Budesonide (0.25 mg/2 mL)
Trial: 17693905
Drug: Inhaled placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo (2 mL of inhaled 0.9% saline)
Trial: 12040440
Drug: BFM-oriented therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFM-oriented therapy without cranial irradiation
Trial: 12040440
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of L-asparaginase (HD-L-ASP) during maintenance treatment
Trial: 12040440
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of intravenous 6-mercaptopurine (HD-6MP) during protocol M
Trial: 31401909
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy (PST-PC)
Trial: 7488410
Drug: EPI 120
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI 120 mg/m2 every 3 weeks
Trial: 7488410
Drug: EPI 120
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI 120 mg/m2 + LND (150 mg on day 1, 300 mg on day 2, 450 mg on days 3-5)
Trial: 2139996
Drug: Verapamil hydrochloride
RxNorm normalized name: Verapamil Hydrochloride
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil hydrochloride aerosol therapy (10 mg/day on days 10, 12, 14, 16, 18, 20, 22)
Trial: 7377255
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of estradiol valerate
Trial: 31464912
Drug: SOCG (SOCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOCG (SOCG tablet)